Mitogen Activated Protein Kinase 14-Pipeline Review H2 2018
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)
(EMAILWIRE.COM, November 24, 2018 ) Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)-Mitogen-activated protein kinase 14 also called p38-alpha is an enzyme belongs to p38 MAPK family. p38-alpha MAPK play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. p38-alpha MAPK is expressed in many cell types. p38-alpha MAPK is implicated in cell apoptosis, proliferation, differentiation, migration, mRNA stability, and inflammatory response in different cell types through variety of different target molecules.
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively.
Download sample copy of this Report: https://www.reportsweb.com/inquiry&RW00012294896/sample
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Oncology, Immunology, Gastrointestinal and Undisclosed which include indications Alzheimer's Disease, Pancreatic Cancer, Acute Ischemic Stroke, Chronic Inflammation, Dilated Cardiomyopathy, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Ischemic Stroke, Multiple Sclerosis, Neuropathic Pain (Neuralgia), Pain, Peritoneal Cancer, Post-Operative Pain, Rheumatoid Arthritis, Ulcerative Colitis and Unspecified.
The latest report Mitogen Activated Protein Kinase 14-Pipeline Review, H2 2018, outlays comprehensive information on the Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects.
Get More Information about this Report: https://www.reportsweb.com/inquiry&RW00012294896/buying
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively.
Download sample copy of this Report: https://www.reportsweb.com/inquiry&RW00012294896/sample
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Oncology, Immunology, Gastrointestinal and Undisclosed which include indications Alzheimer's Disease, Pancreatic Cancer, Acute Ischemic Stroke, Chronic Inflammation, Dilated Cardiomyopathy, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Ischemic Stroke, Multiple Sclerosis, Neuropathic Pain (Neuralgia), Pain, Peritoneal Cancer, Post-Operative Pain, Rheumatoid Arthritis, Ulcerative Colitis and Unspecified.
The latest report Mitogen Activated Protein Kinase 14-Pipeline Review, H2 2018, outlays comprehensive information on the Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects.
Get More Information about this Report: https://www.reportsweb.com/inquiry&RW00012294896/buying
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results